Related Experiment Video
Updated: Mar 29, 2026
08:58
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
13.0K
Medical Therapy for Inflammatory Bowel Disease
Panayiotis Grevenitis1, Arul Thomas1, Nilesh Lodhia1
1Division of Gastroenterology & Hepatology, Medical University of South Carolina, 114 Doughty Street, Suite 249, MSC 702, Charleston, SC 29425-2900, USA.
The Surgical Clinics of North America
|November 25, 2015
Summary
Inflammatory bowel disease (IBD) treatments now aim for mucosal healing, not just symptom relief. Achieving endoscopic or histologic remission represents a significant advance in IBD patient care.
Area of Science:
- Gastroenterology and Surgery
- Inflammatory Bowel Disease (IBD) Research
- Pharmacological Therapies
Background:
- Patients with inflammatory bowel disease (IBD) are often managed by surgeons and receive various treatments.
- Therapies include 5-aminosalicylic acid (5-ASA) compounds, steroids, immunomodulators, and biologics.
- The primary goal of these treatments is to reduce intestinal inflammation and enhance patient quality of life.
Purpose of the Study:
- To discuss the evolution of therapeutic endpoints in IBD management.
- To highlight the shift from clinical remission to more stringent goals like endoscopic or histologic remission.
- To emphasize the role of various therapeutic agents in achieving mucosal healing.
Main Methods:
- Review of current therapeutic strategies for IBD.
- Analysis of treatment goals and endpoints in IBD.
- Discussion of pharmacological agents used in IBD management.
Main Results:
- Traditional IBD treatment focused on symptom resolution (clinical remission).
- Advances in therapy allow for more precise endpoints, including endoscopic and histologic remission.
- Mucosal healing is an achievable and desirable outcome with current treatments.
Conclusions:
- Modern IBD therapy enables clinicians to pursue more rigorous treatment targets.
- Achieving mucosal healing is a key objective in managing IBD patients.
- A combination of therapeutic agents can be employed to facilitate mucosal healing.
Keywords:
Crohn's diseaseFistulaFulminant colitisInflammatory bowel diseasePerioperative managementUlcerative colitisMore Related Videos
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
935
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
935
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
669
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
669
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
741
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
741
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
629
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
629
01:29Drugs for Treatment of Ulcerative Colitis in IBD
618
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
618
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
1.0K
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
1.0K